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Abstract 
Objective:  Low plasma adiponectin level can predict the development of hypertension after 
5 years in our population.  We therefore investigated if single nucleotide polymorphisms 
(SNPs) in the adiponectin gene influenced plasma adiponectin level and whether they were 
associated with hypertension.   
Design and Methods:  We genotyped 14 tagging SNPs in 1616 subjects with persistent 
normotensive or hypertensive status during a 6.4-year follow-up period in the Hong Kong 
Cardiovascular Risk Factor Prevalence Study-2 (CRISPS-2).  Plasma adiponectin level was 
measured in 1385 subjects using in-house sandwich enzyme-linked immunosorbent assay.   
Results:  The minor G allele of the SNP rs266729 was significantly associated with higher 
odds of hypertension (odds ratio [95% CI]=1.49 [1.13-1.95], P=0.0044) after adjusting for 
covariates.  In stepwise multiple logistic regression, this SNP (P=0.006) was a significant 
independent factor of hypertension, together with age (P<0.001), body mass index (P<0.001), 
triglycerides (P=0.021), and insulin resistance index (P<0.001).  Among the 14 SNPs, 
rs266729 (β=-0.067, P=0.0037), -10677C>T (β=0.069, P=0.0027), rs182052 (β=-0.097, 
P<0.0001), and rs12495941 (β=0.103, P<0.0001) were significantly associated with 
adiponectin level after adjusting for covariates.  No significant sex-interaction was found for 
the associations of SNPs with hypertension and adiponectin level.  Similar results were 
obtained in haplotype analysis.   
Conclusion:  In our population, genetic variants in the adiponectin gene influenced plasma 
adiponectin levels and one of them was associated with hypertension.  This study has 
provided further evidence for a role of adiponectin in the development of hypertension. 
 
Keywords:  adiponectin; hypertension; gene; single nucleotide polymorphism 
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Introduction 
Adipose tissue has recently been recognized as an endocrine organ.  One of its secretory 
products is adiponectin, which has been shown to increase insulin sensitivity, via promoting 
lipid β-oxidation in skeletal muscles and reducing hepatic gluconeogenesis (1, 2).  It has 
direct vasoprotective actions such as stimulation of prostaglandin I2 synthase and endothelial 
nitric oxide synthase activity (3).  A low circulating level of adiponectin is associated with 
endothelial dysfunction, diabetes, obesity, inflammation, and coronary artery disease (1, 4). 
 
Hypoadiponectinemia is associated with hypertension in cross-sectional case-control studies 
(5, 6).  We and others previously reported that low adiponectin level is predictive of the 
development of hypertension in prospective studies (7, 8).  Genetic factor accounts for about 
40-70% of the variation in adiponectin levels (9).  Genetic variants in the gene encoding 
adiponectin (ADIPOQ) have been reported to be associated with adiponectin level in several 
genome-wide linkage and association studies (9-11).  However, inconsistent findings on the 
association of genetic variants of ADIPOQ with adiponectin level (9-13) and hypertension (5, 
6, 14) have been reported which could be due to difference in ethnic populations, SNP 
selection, and study power.  To our best knowledge, there was no systematic analysis of 
SNPs in ADIPOQ gene with regard to both adiponectin level and hypertension in Chinese 
population.  As female gender is well-known to be associated with higher adiponectin level 
(15), it is worthwhile to investigate if there is any interaction between sex and genetic 
variants on adiponectin level and risk of hypertension.   
 
In this study, we investigated the association of common genetic variants in the ADIPOQ 
gene with adiponectin level and hypertension.  We included subjects with persistent 
normotensive or hypertensive status during a 6.4-year follow-up period in the 
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population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS-2).  
 
Subjects and Methods 
Subjects 
The Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) was a cohort study 
of cardiovascular risk factors in the Hong Kong Chinese (16, 17).  Of the 2895 subjects who 
initially participated (CRISPS-1), 1944 enrolled in the follow-up study (CRISPS-2) in 2000-4 
after a median interval of 6.4 years.  The study protocol was approved by the Ethics 
Committee of the University of Hong Kong.  All subjects gave written consent.  In this 
study, we included all the 285 hypertensive subjects and 1331 normotensive subjects with 
DNA samples available who were either hypertensive or normotensive at baseline and also at 
the 6.4-year follow-up assessment.  As plasma samples were not available for the majority 
of subjects at baseline, adiponectin level was measured only in plasma samples at follow-up 
(n=1385) and thus data at the follow-up were used in all the analyses.  There was no 
significant difference in age, sex, body mass index (BMI), and hypertension prevalence 
between subjects with and without measurement of adiponectin level (all P>0.05). 
 
SNPs selection and genotyping 
Tagging SNPs were selected in the ADIPOQ gene from the HapMap Han Chinese population 
(Phase II data, release 22).  There were 13 tagging SNPs (rs16861194, rs266729, rs182052, 
rs16861205, rs822396, rs12495941, rs7649121, rs7627128, rs1501299, rs3774262, 
rs6773957, rs1063539, and rs12629945) which captured all the 21 SNPs from 5kb region 
upstream to 2kb downstream of the gene (position 188,038,157-188,060,946, GenBank 
accession number NC_000003, NCBI build 36) with r2 ≥0.9 and minor allele frequency 
(MAF) ≥0.05.  However, genotyping was not performed for the SNP rs7627128 as it could 
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not be incorporated into Sequenom multiplex assay.  This SNP showed a r2 of 0.85 with 
rs7649121 and a r2 of 0.53 with rs266729.  In addition, three SNPs (rs822395, rs2241766, 
and -10677C>T) identified in our previous study (18), but not in the HapMap project, were 
also genotyped in this study.  Genotyping was performed using the MassARRAY system 
(Sequenom, San Diego, CA) with the iPLEXTM assay in the Genome Research Centre, 
University of Hong Kong. 
 
Phenotypes and other variables of interest 
Hypertension was defined as blood pressure ≥140/90 mmHg or on anti-hypertensive 
medication.  Pulse pressure was defined as the difference between systolic and diastolic 
blood pressure.  Mean arterial pressure (MAP) was calculated as the sum of diastolic blood 
pressure and one-third of the pulse pressure.  Blood pressure was measured as described 
previously (16, 17).  Circulating total adiponectin level was measured with an in-house 
sandwich enzyme-linked immunosorbent assay established in our laboratory (intra-assay and 
inter-assay coefficients of variation of 6.2-8.3% and 5.1-6.4% respectively) (19).  Plasma 
high sensitivity C-reactive protein (hsCRP) was measured as described previously (20, 21).  
Drinking was defined as consumption of alcoholic drinks at least once a week.  Regular 
exercise was defined as having exercise for ≥30 minutes at least once a week in the past 
month.  Smoking was defined as ever smoking in their lives.  Other clinical parameters 
such as glucose, insulin, and lipid profile were measured as described previously (16, 17). 
 
Statistical analysis 
Haploview version 4.1 was used to assess linkage disequilibrium (LD) (22).  Analysis of 
SNPs and haplotypes were performed using program PLINK (version 1.0.6) (23).  Variables 
with skewed distributions were ln-transformed before analysis.  Multivariate logistic or 
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linear regression models were used to estimate the odds ratios (OR) or regression coefficients 
under the assumption of an additive effect of allele dosage.  Correction for multiple testing 
was performed by the SNP spectral decomposition method (SNPSpD) (24).  Under this 
method, the effective number of independent marker loci (MeffLi) was 9 and the 
experimental-wide significance threshold to keep type 1 error rate at 5% was 0.0057.  
Correction for testing of multiple phenotypes was not performed as the phenotypes tested 
were closely related to each other.  The P values for interaction were estimated by including 
the multiplicative interaction term in the multivariate regression models in full sample after 
adjusting for the main effects of all covariates. 
 
In PLINK, haplotypes were inferred using the expectation-maximization algorithm.  For 
haplotype analysis, only haplotypes with frequency >0.05 were tested.  An omnibus test was 
performed to assess the global P value of the overall variation at the locus.   
 
Results 
Subject characteristics and genotyping 
Table 1 shows the characteristics of the 1616 subjects in the sub-cohort who were persistently 
hypertensive (n=285) or normotensive (n=1331) during the 6.4-year follow-up period.  As 
expected, hypertensive subjects had worse cardiovascular risk profile and lower adiponectin 
level (P<0.001) than the normotensive subjects.   
 
Among the 15 SNPs genotyped, only the SNP rs7649121 showed significant deviation from 
Hardy-Weinberg equilibrium (P<0.0001 among all subjects or among case- and 
control-specific subgroups) and was excluded from subsequent analysis.  This SNP also 
showed significant deviation from Hardy-Weinberg equilibrium in the HapMap Han Chinese 
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population (P=0.0056).  The genotyping rates of the remaining 14 SNPs were all ≥99.2%.  
There were 5 SNP pairs showing high pairwise LD pattern (SNPs 1 & 5, SNPs 6 & 7, SNPs 9 
& 11, SNPs 9 & 13 and SNPs 11 & 13; all r2>0.80). 
 
Hypertension 
Among the 14 SNPs, the minor allele of SNP 2 was significantly associated with higher odds 
of hypertension after adjusting for age and sex, and correction for multiple testing (P=0.0044) 
(Table 2).  The association remained significant after further adjusting for BMI, 
triglycerides, high-density lipoprotein (HDL) cholesterol, homeostasis model assessment of 
insulin resistance index (HOMA-IR), and 2-h post-oral glucose tolerance test (OGTT) 
glucose (OR [95% CI] = 1.49 (1.13-1.95), P=0.0044).  In a separate analysis, similar results 
was obtained under the assumption of dominant allelic effect (P=0.0024 in full adjustment 
model).  None of the SNP showed significant sex-interaction (P>0.05).  In forward 
stepwise multiple logistic regression, this SNP was a significant independent factor of 
hypertension (Table 3). 
 
The minor allele of SNP 2 was associated with higher percentage of taking anti-hypertensive 
medication (12.2%, 16.1%, and 17.3% for subjects with CC, CG, and GG genotypes 
respectively, P=0.004) and no significant association was found with other clinical 
characteristics (data not shown).  To examine the relationship between SNP 2 genotype and 
blood pressure traits, we adjusted the blood pressure values in subjects on anti-hypertensive 
medication by adding 10 and 5 mmHg to systolic and diastolic blood pressures respectively 
(25).  Using this method, the minor allele of SNP 2 was associated with higher diastolic 
blood pressure after adjusting for age, sex, BMI, triglycerides, HDL cholesterol, HOMA-IR, 
and 2-h post-OGTT glucose (β=0.053, P=0.019).  The diastolic blood pressures (mean±S.D.) 
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was 74.4±10.2, 75.2±11.0, and 75.7±10.7 mmHg in subjects with CC, CG, and GG 
genotypes respectively.  There was no significant sex-interaction (P for interaction=0.669). 
 
Plasma adiponectin level 
Among the 1385 subjects with adiponectin level measured, the level was negatively 
correlated with BMI, waist circumference, blood pressure, MAP, triglycerides, low-density 
lipoprotein (LDL) cholesterol, fasting glucose, 2-h post-OGTT glucose, fasting insulin, 
HOMA-IR and hsCRP, and positively correlated with age and HDL cholesterol (all P<0.05 
after adjusting for age and sex, where appropriate).  The level was significantly higher in 
women (P<0.001) and was not related to drinking, smoking, and regular exercise (P>0.05).  
Among hypertensive subjects, the level was significantly lower in subjects with 
anti-hypertensive medication treatment than those without (geometric mean [95% CI] = 5.78 
[5.34-6.26] and 7.83 [6.35-9.66] mg/l respectively, P<0.001 after adjusting for age and sex).  
In forward stepwise multiple linear regression, female gender, higher age, lower BMI, lower 
triglycerides, higher HDL cholesterol, lower 2-h post-OGTT glucose, and lower HOMA-IR 
are independent factors associated with higher adiponectin level, explaining 31.3% variation 
in adiponectin level (Table 4).  Sex-specific analysis showed similar results (data not shown).  
Therefore, in all subsequent analysis of adiponectin level, all models were adjusted for age, 
sex, BMI, triglycerides, HDL cholesterol, 2-h post-OGTT glucose, and HOMA-IR. 
 
Several genetic variants were significantly associated with adiponectin level after adjusting 
for covariates (Figure 1A).  The minor alleles of SNPs 2 and 4 were significantly associated 
with lower level (β=-0.067, P=0.0037 and β=-0.097, P<0.0001 respectively) whereas the 
minor alleles of SNPs 3 and 8 were significantly associated with higher level (β=0.069, 
P=0.0027 and β=0.103, P<0.0001 respectively).  None of the SNP showed significant 
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sex-interaction (P>0.05).  Figure 1B shows the unadjusted geometric mean (95% CI) of 
adiponectin level stratified by the genotypes of these four SNPs in men and women. 
 
Haplotype analysis 
Haplotypes was constructed using the SNPs 2, 3, 4, and 8 as these SNPs showed significant 
association with adiponectin level.  There were four common haplotypes with frequency 
>5%, namely, CCGT (36.2%), GCAG (24.1%), CCAG (16.2%), and CCGG (16.1%).   
Haplotype analysis revealed significant associations with both adiponectin level and 
hypertension (global P<0.001 and 0.01 respectively after adjusting for covariates).  
However, the overall haplotype association with adiponectin level became non-significant 
after controlling for the SNPs 4 (P=0.085) or 8 (P=0.217) alone, but not SNPs 2 (P=0.0007) 
or 3 (P=0.0007), suggesting that the significant haplotype association was mainly contributed 
by SNPs 4 and 8.  Similarly, the overall haplotype association with hypertension became 
non-significant after controlling for the SNP 2 (P=0.124) alone, but not SNPs 3 (P=0.011), 4 
(P=0.005), or 8 (P=0.004), suggesting that the significant haplotype association was mainly 
contributed by SNP 2.   
 
Discussion 
In this study, we showed that four genetic variants, namely rs266729 (-11377C>G), 
-10677C>T, rs182052 (-10066G>A), and rs12495941 (-2668G>T) were associated with 
adiponectin level, with the effect being stronger for rs182052 and rs12495941.  Among 
these SNPs, rs266729, and -10677C>T are located in the gene promoter region whereas 
rs182052 and rs12495941 are located in the intron 1 region.  When compared with other 
previous studies, there seems to be ethnic difference in the associations of genetic variants 
with adiponectin level.  For example, in the Genetic Epidemiology of Metabolic Syndrome 
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Study, SNPs rs3774261 (712A>G) and rs6773957 (which were almost in complete LD) were 
the most strongly associated SNPs in ADIPOQ gene in Northern and Western European 
populations (11).  In both the Insulin Resistance and Atherosclerosis Study Family Study 
and the Framingham Offspring Study (9, 12), the most strongly associated SNP was 
rs1700539 (-11391G>A), which was not found in our population (18). 
 
Based on the Alibaba2.1 program (26), the SNP rs12495941 is not involved in any putative 
transcription binding site whereas the presence of the minor allele of the SNP rs182052 
results in a loss of a Sp1 binding site and gain of a CCAAT/enhancer binding protein (C/EBP) 
β binding site.  Both binding sites are involved in adipocyte differentiation (27, 28).  It has 
been shown that the first intron of the human ADIPOQ gene contains a gene expression 
enhancer element which responds to C/EBP α, but not C/EBP β (29).  It is interesting to 
investigate whether this enhancer element could also respond to Sp1. 
 
Previous association studies on hypertension produced inconsistent results, likely due to 
small contribution of individual genes, inadequate power for multiple testing, and 
confounding by environmental factors.  In this study, we included only subjects who were 
persistently hypertensive or normotensive for the entire 6.4-year follow-up period.  This 
could help to minimize the confounding effect of environmental factors and phenotype 
misclassification, and hence improve our power.  In this way, our study is cross-sectional 
and may not establish the causal relationship between genetic variants in the ADIPOQ gene 
and hypertension.  However, given that we have shown previously in a sub-cohort of the 
CRISPS study that hypoadiponectinemia is a predictor of hypertension at year 5 (7) and 
genotypes are randomly assigned at conception, the finding of the SNP rs266729, associated 
with both adiponectin level and hypertension, may provide further supporting evidence for a 
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role of adiponectin in the development of hypertension.  This SNP showed a difference in 
MAF of about 4.4% between hypertensive and normotensive subjects, and a difference in 
diastolic blood pressure of about 1.3 mmHg between subjects with CC and GG genotypes.  
Such small effect size is consistent with the findings from recent genome-wide association 
studies (30, 31).  Nevertheless, our findings will need to be confirmed by an independent 
larger prospective cohort with a better power to detect associations with smaller effect size. 
 
We and other previously reported that the SNP rs2241766 (45T>G) was associated with or 
predict the development of diabetes or hyperglycemic status (18, 32).  Although 
dysglycemia and raised blood pressure co-exist in a large proportion of subjects in our local 
population (17), it was rs266729, rather than rs2241766, that was associated with 
hypertension.  Interestingly, rs266729 has been reported to be associated with diabetes, 
severe forms of obesity, carotid intima media thinkness, and other cardiovascular risks 
(33-37).  This SNP was associated with adiponectin level in Caucasians (10, 33, 38).  This 
SNP was also associated with diabetic nephropathy in female type 1 diabetic patients and the 
presence of the minor G allele was shown to destroy the binding site of transcriptional 
stimulatory protein, Sp1 (39).  In a recent study, the minor allele of this SNP showed altered 
DNA binding activity, leading to lower basal and inducible promoter activity in mouse 
3T3-L1 adipocytes (40). 
 
A recent study has demonstrated the significant genetic correlation of plasma adiponectin 
with HDL cholesterol and fasting insulin (41), in keeping with the well-known close 
association of hypoadiponectinemia with insulin resistance (1), an established risk factor for 
hypertension.  Hypoadiponectinemia may also cause hypertension through several potential 
mechanisms such as insulin resistance, sympathetic activation, increased circulating fatty acid 
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levels via reduced fatty acid oxidation, impaired endothelium-dependent vasodilation, and 
vascular inflammation (7).  Although hypertension was associated with lower adiponectin 
level (5-7), there were only few studies on the association of genetic variants with 
hypertension, which were all in Asians.  One study in Taiwan only genotyped the SNP 
rs2241766 (45T>G) and reported no significant association with hypertension (6).  Another 
Chinese study only genotyped the SNPs rs2241766 (45T>G) and rs1501299 (276G>T), and 
reported no significant association with hypertension (14).  In a Japanese study which 
examined two SNPs in men subjects, a rare genetic variant, I164T (with MAF of 1.5% in 
hypertensive subjects and 0.2% in normotensive subjects), has been shown to be associated 
with lower adiponectin level and higher odds of hypertension (5).  Although rare mutation 
in key regulatory pathway can often give rise to extreme phenotypes, it is unlikely to be the 
cause of common multifactorial diseases like hypertension in the general population (42).   
 
In conclusion, several genetic variants in the ADIPOQ gene were associated with adiponectin 
level in this Chinese population and among these variants, the SNP rs266729 was associated 
with hypertension among subjects who were persistently hypertensive or normotensive 
during a 6.4-year follow-up period.  No significant sex-interaction was found between 
genetic variants and adiponectin level or hypertension.  Taken together with previous reports 
on hypoadiponectinemia in the prediction of hypertension (7, 8), our study has provided 
further evidence for a role of adiponectin in the development of hypertension. 
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Figure 1.  Associations of SNPs with adiponectin level.  (A) The bar shows the magnitude 
of β coefficients in multiple linear regression analysis of adiponectin level (ln-transformed) 
20 
 
21 
 
after adjusting for age, sex, BMI, triglycerides (ln-transformed), HDL cholesterol, 2-h 
post-OGTT glucose (ln-transformed), and HOMA-IR (ln-transformed).  *P values that can 
pass multiple testing correction (P<0.0057).  (B)  Unadjusted geometric mean of plasma 
adiponectin level stratified by different genotypes of the four SNPs that showed significant 
association with plasma adiponectin.  The error bar shows the 95% CI of the geometric 
mean.  Men and women are represented by a square and a triangle respectively. 
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Table 1  Clinical characteristics of the 1616 subjects at the follow-up. 
Normotensive (n=1331) Hypertensive (n=285) 
Age, years 48.8±10.5 63.2±9.9‡ 
Women, % 56.0 50.9 
BMI, kg/m2 23.5±3.3 26.5±3.9‡ 
Waist circumference, cm 78.0±9.4 85.9±10.0‡ 
Systolic blood pressure, mmHg§ 113.9±11.3 153.9±14.3‡ 
Diastolic blood pressure, mmHg§ 72.1±8.2 86.3±12.7‡ 
Pulse pressure, mmHg§ 41.8±9.0 67.6±15.8‡ 
MAP, mmHg§ 86.0±8.3 108.9±11.0‡ 
Triglycerides, mmol/l 1.09 (1.07-1.12) 1.49 (1.41-1.58)‡ 
HDL cholesterol, mmol/l 1.37±0.37 1.24±0.34‡ 
LDL cholesterol, mmol/l 3.24±0.80 3.54±0.90* 
Fasting glucose, mmol/l 5.14 (5.09-5.18) 5.90 (5.74-6.05)‡ 
2-h post-OGTT glucose, mmol/l 6.55 (6.43-6.67) 8.38 (7.99-8.78)‡ 
Fasting insulin, mIU/l 6.91 (6.72-7.10) 10.10 (9.41-10.84)‡ 
HOMA-IR 1.58 (1.53-1.63) 2.65 (2.44-2.87)‡ 
hsCRP, mg/l 0.61 (0.57-0.65) 1.18 (1.05-1.34)‡ 
Adiponectin, mg/l║   
Men 5.63 (5.34-5.94) 5.26 (4.71-5.87)‡ 
Women 7.91 (7.56-8.28) 7.11 (6.44-7.86)‡ 
Smoking, % 29.8 31.6 
Drinking, % 9.8 9.2 
Regular exercise, % 29.2 44.3 
Anti-hypertensive medication, % - 79.3 
Data are expressed as mean±S.D. or geometric mean (95% CI) unless otherwise stated.  
*P<0.05, †P<0.01, and ‡P<0.001 for normotensive versus hypertensive subjects after 
adjusting for age and sex, where appropriate.   
§Subjects on anti-hypertensive medication were excluded (n=226).   
23 
 
║Data were available in 1145 normotensive (514 men and 631 women) and 240 hypertensive 
(120 men and 120 women) subjects. 
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Table 2  Associations of SNPs with hypertension. 
No. SNP Alleles (Major: minor) MAF OR (95% CI) P 
   NT HT   
1 rs16861194 A:G 0.168 0.147 0.82 (0.62-1.10) 0.186 
2 rs266729 C:G 0.239 0.283 1.40 (1.11-1.77) 0.0044† 
3 -10677C>T* C:T 0.064 0.070 1.10 (0.73-1.66) 0.660 
4 rs182052 G:A 0.407 0.428 1.17 (0.94-1.44) 0.162 
5 rs16861205 G:A 0.161 0.144 0.83 (0.62-1.11) 0.200 
6 rs822395 A:C 0.151 0.151 0.85 (0.63-1.16) 0.300 
7 rs822396 A:G 0.133 0.125 0.78 (0.56-1.08) 0.140 
8 rs12495941 G:T 0.419 0.412 1.01 (0.82-1.25) 0.903 
9 rs2241766 T:G 0.298 0.288 0.99 (0.79-1.24) 0.933 
10 rs1501299 G:T 0.260 0.275 1.06 (0.85-1.33) 0.613 
11 rs3774262 G:A 0.301 0.290 1.00 (0.80-1.25) 0.989 
12 rs6773957 A:G 0.441 0.439 0.97 (0.79-1.20) 0.778 
13 rs1063539 G:C 0.296 0.291 1.02 (0.81-1.28) 0.875 
14 rs12629945 G:A 0.184 0.173 0.99 (0.75-1.30) 0.933 
HT, hypertension; NT, normotension. 
All OR and P values were adjusted for age and sex. 
*No rs number is assigned for this SNP. 
†P values that can pass multiple testing correction (P<0.0057). 
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Table 3  Stepwise multiple logistic regression for hypertension in the sub-cohort of 1616 
subjects. 
Parameter OR (95% CI) P 
Age, years 1.14 (1.12-1.16) <0.001 
BMI, kg/m2 1.19 (1.12-1.25) <0.001 
Triglycerides, mmol/l (ln-transformed) 1.56 (1.07-2.28) 0.021 
HOMA-IR (ln-transformed) 2.14 (1.51-3.04) <0.001 
SNP 2 (rs266729) 1.46 (1.11-1.92) 0.006 
Nagelkerke r2 0.444  
Age, sex, BMI, triglycerides (ln-transformed), HDL cholesterol, 2-h post-OGTT glucose 
(ln-transformed), HOMA-IR (ln-transformed), hsCRP (ln-transformed), and SNP 2 were 
allowed to enter into the stepwise model. 
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Table 4  Stepwise multiple linear regression for adiponectin level (ln-transformed). 
Parameter β P 
Age, y 0.213 <0.001 
Female gender 0.154 <0.001 
BMI, kg/m2 -0.091 0.001 
Triglycerides, mmol/l (ln-transformed) -0.098 <0.001 
HDL cholesterol, mmol/l 0.234 <0.001 
2-h post-OGTT glucose, mmol/l (ln-transformed) -0.098 <0.001 
HOMA-IR (ln-transformed) -0.140 <0.001 
R2 0.313  
Age, sex, BMI, systolic blood pressure, MAP, triglycerides (ln-transformed), HDL 
cholesterol, 2-h post-OGTT glucose (ln-transformed), HOMA-IR (ln-transformed), and 
hsCRP (ln-transformed) were allowed to enter into the stepwise model. 
 
 
  
 
